John A. Glaspy

Q: What Schools Are Affiliated With John A. Glaspy

John A. Glaspy is affiliated with the following schools: University of Sydney, University of California, Los Angeles, Massachusetts General Hospital

John A. Glaspy's AcademicInfluence.com Rankings

John A. Glaspy

Philosophy

#7062

World Rank

#10218

Historical Rank

Logic

#4141

World Rank

#5397

Historical Rank

philosophy Degrees

Download Badge

Philosophy

John A. Glaspy's Degrees

Doctorate Medicine University of California, San Francisco
Bachelors Biological Sciences Stanford University

Why Is John A. Glaspy Influential?

(Suggest an Edit or Addition)

(See a Problem?)

John A. Glaspy's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

PD-1 blockade induces responses by inhibiting adaptive immune resistance (2014) (4971)
Adjuvant trastuzumab in HER2-positive breast cancer. (2011) (1199)
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. (1998) (1107)
Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer (1991) (1086)
RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. (2011) (961)
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. (2014) (835)
Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. (1997) (697)
Differential effects of prostaglandin derived from ω-6 and ω-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion (2003) (575)
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. (2009) (574)
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. (2005) (565)
Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. (2002) (510)
Thrombocytopenia caused by the development of antibodies to thrombopoietin. (2001) (493)
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. (2017) (426)
Adjuvant Trastuzumab in HER 2-Positive Breast Cancer (2011) (383)
A comparison of gene transfer methods in human dendritic cells. (1997) (333)
Electroacupuncture for control of myeloablative chemotherapy-induced emesis: A randomized controlled trial. (2000) (320)
Current developments in cancer vaccines and cellular immunotherapy. (2003) (300)
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. (2017) (295)
Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. (2003) (289)
PD-1 Blockade Expands Intratumoral Memory T Cells (2016) (288)
Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. (1997) (282)
Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. (2002) (277)
Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. (2003) (267)
Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. (1997) (265)
Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. (1998) (262)
Cancer Detection with Whole‐Body PET Using 2‐[18F]Fluoro‐2-Deoxy‐D-Glucose (1993) (254)
Interferon‐α and granulocyte‐macrophage colony‐stimulating factor differentiate peripheral blood monocytes into potent antigen‐presenting cells (1998) (249)
Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer (2010) (247)
Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy (2002) (214)
Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. (2011) (210)
Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes (2010) (204)
Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma (2009) (204)
The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. (1992) (201)
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. (2013) (199)
Use of complementary/alternative therapies by women with advanced-stage breast cancer (2002) (197)
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. (2012) (197)
Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. (2008) (195)
Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. (1997) (194)
Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway (2011) (193)
Clinical update: intravenous iron for anaemia (2007) (189)
A Phase I/II Trial Testing Immunization of Hepatocellular Carcinoma Patients with Dendritic Cells Pulsed with Four α-Fetoprotein Peptides (2006) (184)
Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma (2014) (183)
Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor. (1988) (180)
Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy (2002) (177)
Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. (2002) (174)
Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. (1999) (170)
T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. (2003) (166)
Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. (1998) (164)
Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer (2018) (163)
RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). (2009) (162)
Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. (1997) (154)
Effect of Altering Dietary ω-6/ω-3 Fatty Acid Ratios on Prostate Cancer Membrane Composition, Cyclooxygenase-2, and Prostaglandin E2 (2006) (153)
Modulation of omega-3/omega-6 polyunsaturated ratios with dietary fish oils in men with prostate cancer. (2001) (148)
Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. (1998) (142)
Fatty acid modulation of MCF-7 human breast cancer cell proliferation, apoptosis and differentiation. (2002) (140)
CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans (2011) (139)
Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. (2009) (137)
Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine. (1991) (137)
Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. (2017) (136)
A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. (2006) (133)
α-Fetoprotein-specific Genetic Immunotherapy for Hepatocellular Carcinoma (1999) (133)
Long-Chain n-3-to-n-6 Polyunsaturated Fatty Acid Ratios in Breast Adipose Tissue From Women With and Without Breast Cancer (2002) (126)
Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade (2009) (123)
T Cell Responses to HLA-A*0201-Restricted Peptides Derived from Human α Fetoprotein1 (2001) (120)
Adenovirus MART-1–engineered Autologous Dendritic Cell Vaccine for Metastatic Melanoma (2008) (119)
Differential response of triple‐negative breast cancer to a docetaxel and carboplatin‐based neoadjuvant treatment (2010) (119)
Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. (2003) (119)
Whole body skeletal imaging with [18F]fluoride ion and PET. (1993) (118)
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. (2019) (118)
Role of Dendritic Cell Phenotype, Determinant Spreading, and Negative Costimulatory Blockade in Dendritic Cell-Based Melanoma Immunotherapy (2004) (118)
The effect of anemia treatment on selected health-related quality-of-life domains: a systematic review. (2003) (114)
Imaging of pulmonary mass lesions with whole‐body positron emission tomography and fluorodeoxyglucose (1993) (113)
Iron deficiency anemia--bridging the knowledge and practice gap. (2014) (112)
Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. (2003) (110)
Quantification of Glucose Utilization in Liver Metastases: Parametric Imaging of FDG Uptake with PET (1992) (107)
p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma. (1999) (106)
A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. (2003) (104)
alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. (2001) (103)
Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. (1993) (102)
A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. (1999) (102)
Do We Need a Different Set of Response Assessment Criteria for Tumor Immunotherapy? (2009) (99)
Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. (2010) (98)
In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. (1996) (97)
BRAF V600E inhibition in anaplastic thyroid cancer. (2013) (97)
Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. (2006) (97)
Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines† (2018) (95)
Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. (2005) (95)
Dietary modulation of omega-3/omega-6 polyunsaturated fatty acid ratios in patients with breast cancer. (1997) (95)
Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer. (2000) (95)
Comparison of the isoelectric focusing patterns of darbepoetin alfa, recombinant human erythropoietin, and endogenous erythropoietin from human urine. (2002) (89)
A randomized, active‐control, pilot trial of front‐loaded dosing regimens of darbepoetin‐alfa for the treatment of patients with anemia during chemotherapy for malignant disease (2003) (88)
Cancer immunotherapy using gene-modified dendritic cells. (2002) (87)
Therapeutic options in the management of renal cell carcinoma. (2002) (86)
In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2. (1997) (86)
A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy (2001) (85)
Integrated human T-cell leukemia virus II genome in CD8 + T cells from a patient with "atypical" hairy cell leukemia: evidence for distinct T and B cell lymphoproliferative disorders. (1988) (84)
Heterogeneity of epidemic Kaposi's sarcoma. Implications for therapy (1986) (84)
Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study (2016) (84)
Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. (1999) (83)
Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. (2006) (83)
Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations (2011) (83)
Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer (2001) (82)
T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. (2001) (81)
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma (2008) (79)
Quantitative PET imaging of bone marrow glucose metabolic response to hematopoietic cytokines. (1995) (78)
The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. (1993) (78)
A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer (2003) (78)
The impact of epoetin alfa on quality of life during cancer chemotherapy: a fresh look at an old problem. (1997) (77)
PET cancer evaluations with FDG. (1991) (77)
The role of positron emission tomography in oncology and other whole-body applications. (1992) (75)
Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells. (2000) (75)
MDX-010 (human anti-CTLA4): a phase I trial in malignant melanoma (2002) (71)
In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial. (1996) (70)
Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. (2015) (68)
Chronic lymphocytic leukemia and the central nervous system (1996) (67)
Immunosensitization of Tumor Cells to Dendritic Cell-Activated Immune Responses with the Proteasome Inhibitor Bortezomib (PS-341, Velcade)1 (2006) (67)
Role of iron in optimizing responses of anemic cancer patients to erythropoietin. (1999) (63)
Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study. (2018) (63)
Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations (2017) (62)
Hemostatic abnormalities in multiple myeloma and related disorders. (1992) (61)
Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204). (2019) (60)
Erythropoietin in cancer patients. (2009) (60)
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. (2021) (57)
Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human alpha-fetoprotein. (2000) (56)
Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy. (2002) (55)
Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. (2018) (55)
Organochlorine pesticide content of breast adipose tissue from women with breast cancer and control subjects. (2000) (54)
Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. (2003) (54)
High-molecular weight iron dextran: a wolf in sheep's clothing? (2008) (54)
Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice (2016) (53)
Use of positron emission tomography in oncology. (1993) (52)
Results of a multicenter, randomized, double‐blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma (2009) (51)
CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells. (2001) (51)
Are there clinical benefits with early erythropoietic intervention for chemotherapy‐induced anemia? (2006) (51)
A prospective, multi‐center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON‐IDA trial (2019) (50)
Comparison of Subgroup Analyses of PFS from Three Phase III Studies of Bevacizumab in Combination with Chemotherapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC). (2009) (50)
Anemia and fatigue in cancer patients (2001) (50)
Incidence of tumor-cell contamination in leukapheresis products of breast cancer patients mobilized with stem cell factor and granulocyte colony-stimulating factor (G-CSF) or with G-CSF alone. (1999) (49)
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204) (2021) (48)
Relationship between human T cell leukemia virus-II and atypical hairy cell leukemia: a serologic study of hairy cell leukemia patients. (1987) (47)
Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies (2015) (47)
Positron Emission Tomography Diagnosis Of Pulmonary Metastases In Osteogenic Sarcoma (1994) (46)
Neutropenia in an extremely premature infant treated with recombinant human granulocyte colony-stimulating factor. (1991) (46)
5016 Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) (2009) (45)
Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells (1999) (44)
Definition of an Immunologic Response Using the Major Histocompatibility Complex Tetramer and Enzyme-Linked Immunospot Assays (2006) (43)
Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice. (2000) (43)
Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation (2000) (43)
Recombinant human granulocyte colony-stimulating factor increases circulating burst forming unit-erythron and red blood cell production in patients with severe human immunodeficiency virus infection. (1990) (43)
Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials. (2002) (42)
A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial (2016) (42)
Production of functional myeloid cells from CD34‐selected hematopoietic progenitor cells using a clinically relevant ex vivo expansion system (1994) (42)
Megakaryocyte growth and development factor (MGDF) moderately enhances in-vitro platelet aggregation. (1995) (42)
The effects of a high‐fat meal on single‐dose vemurafenib pharmacokinetics (2014) (41)
Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. (2012) (41)
Pulmonary toxicity of high-dose chemotherapy for breast cancer: a non-invasive approach to diagnosis and treatment (1997) (39)
Granulocyte colony-stimulating factor (G-CSF): preclinical and clinical studies. (1992) (39)
Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia. (2005) (39)
Clinical benefits of epoetin alfa therapy in patients with lung cancer. (2002) (38)
Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion (2012) (38)
Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells. (2000) (37)
Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy. (2002) (37)
Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy. (1999) (37)
Hypophosphatemia Associated with Intravenous Iron Therapies for Iron Deficiency Anemia: A Systematic Literature Review (2020) (35)
Clinical Benefit Rate and Time to Response in RIBBON-1, a Randomized, Double-Blind, Phase III Trial of Chemotherapy with or without Bevacizumab (B) for the First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (MBC). (2009) (35)
Thalidomide and chemotherapy combination. (1997) (34)
Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer (2020) (34)
Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells (2005) (34)
Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma (2010) (34)
Phase I study of PD 0332991, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole for first-line treatment of patients with ER-positive, HER2-negative breast cancer. (2010) (33)
Hyperammonemia following allogeneic bone marrow transplantation (1991) (33)
Phase 1 trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma (2005) (32)
Erythropoiesis-stimulating agents in oncology. (2008) (32)
Erythropoietins should be used according to guidelines. (2008) (31)
A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia (2014) (31)
Whole-body positron emission tomography with (fluorine-18)-2-deoxyglucose can detect metastatic carcinoma of the fallopian tube. (1993) (29)
Status of high-dose chemotherapy for breast cancer: a review. (2000) (28)
Enhanced Tumor Responses to Dendritic Cells in the Absence of CD8-Positive Cells1 (2004) (28)
Reductions in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy (2012) (27)
Culture conditions affect the ability of ex vivo expanded peripheral blood progenitor cells to accelerate hematopoietic recovery. (2002) (26)
Novel Interactions of Vitamin E and Estrogen in Breast Cancer (2005) (26)
Standards of care for anemia management in oncology (2002) (25)
Can Erythropoietin Therapy Improve Survival? (2004) (25)
Positron emission tomography scanning in cancer. (1994) (25)
Clinical trials of myeloid growth factors. (1990) (24)
Cancer patient survival and erythropoietin. (2005) (24)
A phase II study of neoadjuvant docetaxel/carboplatin with or without trastuzumab in locally advanced breast cancer: Response and cardiotoxicity. (2006) (23)
Clinical applications of the myeloid growth factors. (1989) (23)
Roxadustat for the treatment of anemia in patients with lower‐risk myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study (2021) (23)
Results of a multicenter, randomized, double‐blind, dose‐evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma (2009) (23)
Antitumor protection using murine dendritic cells pulsed with acid-eluted peptides from in vivo grown tumors of different immunogenicities. (1999) (23)
Economic considerations in the use of peripheral blood progenitor cells to support high-dose chemotherapy (1999) (21)
Hematopoietic management in oncology practice. Part 1. Myeloid growth factors. (2003) (21)
Update on safety of ESAs in cancer-induced anemia. (2012) (21)
Clinical applications of stem cell factor (1996) (21)
Current Status of Use of Erythropoietic Agents in Cancer Patients (2014) (21)
The development of erythropoietic agents in oncology (2005) (20)
A careful reassessment of anthracycline use in curable breast cancer (2021) (20)
Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study. (2013) (20)
The potential for anemia treatment to improve survival in cancer patients. (2002) (20)
Phase I Study of PD 0332991, a Novel, Oral, Cyclin-D Kinase (CDK) 4/6 Inhibitor in Combination with Letrozole, for First-Line Treatment of Metastatic Post-Menopausal, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer. (2009) (20)
The colony-stimulating factors: biology and clinical use. (1990) (19)
A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia. (2007) (19)
Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma. (2007) (18)
The UCLA experience with type I interferons in hairy cell leukemia. (1987) (18)
Randomized, active-controlled, phase , dose-comparison study of NESP administered weekly or every 2 weeks in patients with solid tumors (2001) (18)
Prevention of everolimus/exemestane (EVE/EXE) stomatitis in postmenopausal (PM) women with hormone receptor-positive (HR+) metastatic breast cancer (MBC) using a dexamethasone-based mouthwash (MW): Results of the SWISH trial. (2016) (17)
The health-related quality-of-life impact of histamine dihydrochloride plus interleukin-2 compared with interleukin-2 alone in patients with metastatic melanoma (2003) (17)
A multicenter open-label phase II study of the efficacy and safety of palbociclib a cyclin-dependent kinases 4 and 6 inhibitor in patients with recurrent ovarian cancer. (2016) (17)
Roxadustat (FG4592; ASP1517; AZD9941) in the Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (LR-MDS) and Low Red Blood Cell (RBC) Transfusion Burden (LTB) (2019) (17)
T Cell Responses to HLA-A*0201-Restricted Peptides Derived from Human a Fetoprotein (2001) (17)
Phase 1 clinical trial of anti-CTLA4 human monoclonal antibody CP-675,206 in patients (pts) with advanced solid malignancies. (2004) (17)
Acupuncture: evidence and implications for cancer supportive care. (2001) (16)
Phase II clinical trial with a second generation, GM-CSF encoding, oncolytic herpesvirus in unresectable metastatic melanoma. (2009) (16)
Whole body FDG PET imaging for staging of malignant melanoma: Is it cost effective? (1994) (16)
Effect of anti-CTGF human recombinant monoclonal antibody pamrevlumab on resectability and resection rate when combined with gemcitabine/nab-paclitaxel in phase 1/2 clinical study for the treatment of locally advanced pancreatic cancer patients. (2018) (16)
Anaemia Management Strategies: Optimising Treatment Using Epoetin Beta (NeoRecormon®) (2005) (16)
High-dose chemotherapy and hematopoietic stem cell rescue for breast cancer: experience in California. (2000) (16)
Pharmacokinetics of Histamine Dihydrochloride in Healthy Volunteers and Cancer Patients: Implications for Combined Immunotherapy with Interleukin‐2 (2002) (15)
A Randomized Phase II Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Patients with Advanced Gastrointestinal Stromal Tumors (2021) (15)
Adult‐onset cyclic neutropenia responsive to cyclosporine therapy in a patient with ankylosing spondylitis (1993) (15)
Relationship between omega-3 and omega-6 fatty acid ratios and breast cancer. (1997) (15)
Cost health literacy as a physician skill-set: the relationship between oncologist reported knowledge and engagement with patients on financial toxicity (2020) (15)
Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene–modified dendritic cell vaccines (2002) (15)
Final results of a phase 3, randomized, open-label study of darbepoetin alfa 200 mcg every 2 weeks (Q2W) versus epoetin alfa 40,000 U weekly (QW) in patients with chemotherapy-induced anemia (CIA) (2005) (14)
A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive ovarian cancer. (2013) (14)
Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma (2016) (14)
Impact of epoetin alfa in chemotherapy-associated anemia. (1998) (14)
The impact of granulocyte colony-stimulating factor on quality of life in patients with severe chronic neutropenia. (1991) (13)
Hairy-cell leukemia: biology and treatment. (1986) (13)
A randomized phase II study of nivolumab monotherapy versus nivolumab combined with ipilimumab in advanced gastrointestinal stromal tumor (GIST). (2019) (13)
High-dose vincristine sulfate liposome injection (Marqibo) Is not associated with clinically meaningful hematologic toxicity. (2014) (13)
Evolving therapy of hairy cell leukemia (1987) (13)
Open-label, phase dose escalation study of NESP in patients with chronic anemia of cancer (2001) (12)
Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations. (2002) (12)
Treatment of Hairy Cell Leukemia with Granulocyte Colony‐Stimulating Factor and Recombinant Consensus Interferon or Recombinant Interferon‐Alpha-2b (1992) (12)
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022. (2022) (12)
Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy (2007) (12)
Changes in RBC supportive medications and transfusions in cancer patients undergoing chemotherapy before and after FDA and Medicare actions in 2007 (2008) (11)
Economic outcomes associated with the use of hematopoietic growth factors. (1995) (11)
Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome (2021) (11)
Recombinant beta‐serine‐interferon in hairy cell leukemia compared prospectively with results with recombinant alpha‐interferon (1989) (11)
Corrections to "Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines". (2018) (11)
A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01). (2010) (11)
Opportunistic infections in oncologic patients. (1996) (11)
Cost considerations in therapy with myeloid growth factors. (1993) (11)
Biology and clinical potential of stem-cell factor (1996) (11)
Hematopoietic Management in Oncology Practice (2003) (10)
Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: The FERWON‐IDA/NEPHRO trials (2020) (10)
1120 POSTER Evaluation of the association between hemoglobin (Hb) events and safety outcomes in cancer patients (pts) with chemotherapy-induced anemia (CIA): an integrated analysis of patient-level data from 6 randomized, placebo-controlled trials (RCTs) of darbepoetin alfa (DA) (2007) (10)
Title Combination therapy with vemurafenib ( PLX 4032 / RG 7204 ) and metformin in melanoma cell lines with distinct driver mutations (2011) (10)
Hematopoietic management in oncology practice. Part 2. Erythropoietic factors. (2003) (10)
Talimogene laherparepvec (T-VEC) in combination (combo) with ipilimumab (ipi) versus ipi alone for advanced melanoma: 3-year landmark analysis of a randomized, open-label, phase II trial (2019) (9)
Basic principles of positron emission tomography in oncology: quantitation and whole body techniques. (1994) (9)
Initiation of epoetin‐α therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy (2009) (9)
Improvement in haemoglobin levels improves health-related quality of life (HRQOL) of anaemic cancer patients (2001) (9)
Disturbances in hemostasis in patients with B-cell malignancies. (1992) (9)
Methodological Issues in Trials of Acupuncture—Reply (2001) (9)
Treatment with histamine dihydrochloride and interleukin-2 in patients with advanced metastatic malignant melanoma: a detailed safety analysis (2003) (9)
Broad antitumor protection by dendritic cells administered to CD8α knock out mice (2006) (8)
Abstract C295: Update on first-in-man trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. (2013) (8)
Randomized, single-blind, crossover study to assess the pharmacokinetic and pharmacodynamic bioequivalence of CHS-1701 to pegfilgrastim in healthy subjects. (2017) (8)
Hematology: ESAs to treat anemia—balancing the risks and benefits (2009) (8)
The clinical application of recombinant erythropoietin in the HIV-infected patient. (1994) (8)
Consensus on the use of neutrophil-stimulating hematopoietic growth factors in clinical practice: an international viewpoint. (1997) (8)
Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms. (2009) (8)
An animal model for in vivo evaluation of tumor glycolytic rates with positron emission tomography (1993) (8)
Workup of anemia in cancer. (2020) (8)
Hemoglobin increase is associated with improved health-related quality of life in patients with cancer not receiving chemotherapy. (2003) (8)
Establishing a Denominator for Palliative Care Quality Metrics for Patients with Advanced Cancer. (2018) (8)
Phase III clinical trials with darbepoetin: implications for clinicians. (2005) (7)
Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. (2018) (7)
Chemotherapy-induced anemia: the story of darbepoetin alfa (2013) (7)
Abstract S4-3: Ten-Year Follow-Up Analysis of the BICRG 001 Trial Confirms Superior DFS and OS Benefit of Adjuvant TAC (Docetaxel, Doxorubicin, Cyclophosphamide) over FAC (fluorouracil, Doxorubicin, Cyclophosphamide) in Women with Operable Node-Positive Breast Cancer (2010) (7)
Intravenous iron in chemotherapy and cancer-related anemia (2012) (6)
Overcoming barriers to erythropoietic therapy. Characteristics of darbepoetin alfa and potential advances in scheduling, dosing, and dose-efficiency. (2002) (6)
Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma. (2004) (6)
Clinical applications of filgrastim and stem cell factor in vivo and in vitro. (1994) (6)
1 PD-1 blockade expands intratumoral T memory cells (2016) (6)
Changes in Intratumoral Immune Cell Infiltrates, Foxp3 and Indoleamine 2, 3-Dioxygenase (IDO) Expression With the CTLA4 Blocking MAB CP-675,206 (2006) (6)
Interferon alfa in the postsurgical management of high-risk melanoma: is it worth it? (2009) (6)
Antigen-specific T cell responses in patients with melanoma treated with the CTLA4 blocking mAb ticilimumab. (2006) (6)
Eltrombopag, a novel, oral platelet growth factor, increases platelet counts in thrombocytopenic patients and healthy subjects. (2006) (5)
Financial Toxicity From Generic Specialty Drug Use. (2020) (5)
Abstract CT011: Safety and efficacy results from a phase I dose-escalation trial of the PARP inhibitor talazoparib in combination with either temozolomide or irinotecan in patients with advanced malignancies (2016) (5)
A 6 month extension trial evaluating safety and efficacy of ferric derisomaltose in patients with iron deficiency anemia: The FERWON‐EXT trial (2020) (5)
High-Dose Vincristine Sulfate Liposome Injection (Marqibo®) Is Not Associated With Clinically Meaningful Hematologic Toxicity (2013) (5)
568 Phase I studies with CERA (Continuous Erythropoiesis Receptor Activator), an innovative erythropoietic agent (2003) (5)
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence (2021) (5)
Multiplexed imaging reveals an IFN-γ-driven inflammatory state in nivolumab-associated gastritis (2021) (5)
Overcoming Barriers to Erythropoietic Therapy (2002) (5)
489 Bevacizumab (BV) in combination with chemotherapy in the treatment of HER2-negative metastatic breast cancer (mBC): PFS subgroup results from two phase III studies (2010) (5)
Abstract GS4-01: Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane (2021) (5)
Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin Levels (2020) (4)
Selective and Nonselective Replication of an E 1 B-deleted Adenovirus in Hepatocellular Carcinoma 1 (1999) (4)
317 Safety and efficacy results from a phase 1 dose-escalation trial of the parp inhibitor talazoparib (bmn-673) in combination with either temozolomide or irinotecan in patients with advanced malignancies (2015) (4)
433 Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial (2020) (4)
PS01.59: CheckMate 370: A Master Protocol of Phase 1/2 Studies of Nivolumab as Maintenance or First‐Line ± Standard‐of‐Care Therapies in Advanced NSCLC: Topic: Medical Oncology (2016) (4)
Diagnosis, treatment, and use of intravenous iron for chemotherapy-induced anemia in Europe. (2011) (4)
Long term Survival with CTLA-4 blockade Using Tremelimumab (2016) (4)
Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective (2008) (4)
1129TiPA PHASE 1B/2, MULTICENTER, OPEN LABEL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF TALIMOGENE LAHERPAREPVEC (T-VEC) AND IPILIMUMAB (IPI) VERSUS IPI ALONE IN PREVIOUSLY UNTREATED, UNRESECTED, STAGE IIIB, IIIC, AND IV MELANOMA. (2014) (4)
Phase II clinical trial with a second generation, GM-CSF encoding, oncolytic herpesvirus in unresectable metastatic melanoma (2008) (4)
The Impact of Therapy (Recombinant Granulocyte (1993) (4)
34 – Disorders of Blood Cell Production in Clinical Oncology (2014) (3)
Nutritional, hormonal, and environmental mechanisms in breast tumorigenesis. (1996) (3)
Empirical Criteria for the Selection of Quality-of-Life Instruments for the Evaluation of Peripheral Blood Progenitor Cell Transplantation (1998) (3)
Current Practice In Diagnosis and Treatment of Chemotherapy-Induced Anemia In Five European Countries – A Patient Record Study (2010) (3)
Phase III Studies of Bevacizumab (B) in Combination with Chemotherapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC): Summary of Selected Adverse Events. (2009) (3)
Thrombosis during therapy with erythropoiesis stimulating agents in cancer (2008) (3)
1104 POSTER Patient-level integrated analysis of data from 6 randomized, double-blind, placebo-controlled trials of darbepoetin alfa (DA) in patients (pts) with chemotherapy-induced anemia (CIA) (2007) (3)
Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer. (2021) (3)
The impact of timing of chemotherapy relative to darbepoetin alfa (DA) on DA pharmacokinetics (PK) and hematologic effects (2004) (3)
Introduction. Improving the standard of care in the management of cancer-related anaemia: focus on darbepoetin alfa, a novel erythropoiesis-stimulating protein. (2001) (3)
A Phase II, Randomized, Multi-Centre, Open-Label, Active-Controlled, Dose-Finding Trial of F-627 (benefilgrastim) in Women with Breast Cancer Receiving Myelotoxic Chemotherapy (2014) (3)
[Whole body positron emission tomography in breast cancer]. (1993) (3)
548 CERA (Continuous erythropolesis receptor activator) is an innovative erythropoietic agent with an extended serum half-life: studies of mode of action, pharmacokinetics and erythropoietic activity (2003) (3)
1734PDAnti-CTGF human recombinant monoclonal antibody pamrevlumab increases resectability and resection rate when combined with gemcitabine/Nab-paclitaxel in the treatment of locally advanced pancreatic cancer patients (2017) (3)
The Effect of Hemoglobin (Hb) Level at ESA Initiation on Outcomes in Cancer Patients (pts) with Chemotherapy-Induced Anemia (CIA): A Patient-Based Meta-Analysis from 6 Randomized, Placebo-Controlled Trials (RCTs) of Darbepoetin alfa (DA). (2007) (3)
MACROCYTIC anemias. (1990) (3)
Histamine dihydrochloride administered with interleukin-2 increases survival duration in patients with ocular melanoma with liver metastases (2001) (3)
Current Deve lopments in Cancer Vacc ines and Cel lu lar Immunotherapy (2003) (2)
Epoetin alfa-epbx: a new entrant into a crowded market. a historical review of the role of erythropoietin stimulating agents and the development of the first epoetin biosimilar in the United States (2020) (2)
The promise of colony-stimulating factors in clinical practice. (1990) (2)
Transduction of murine and human tumors using recombinant adenovirus vectors (2006) (2)
Darbepoetin alfa administered at varying intervals compared with weekly epoetin alfa for treating chemotherapy-induced anemia: A pooled analysis of 20 clinical trials. (2006) (2)
Patterns of care in community-based oncology practices for anemia associated with myelosuppressive chemotherapy. (2009) (2)
Hematologic supportive care of the critically ill cancer patient. (2000) (2)
PCN17 COMPARING THE COST-EFFECTIVENESS OF 3 MCG/KG Q2W DARBEPOETIN ALFA WITH STANDARD DOSE EPOETIN ALFA FOR ANEMIA MANAGEMENT IN CHEMOTHERAPY-TREATED CANCER PATIENTS IN UNITED STATES (2002) (2)
Adherence to anemia treatment guidelines in U.S. community oncology practices (2007) (2)
Factors associated with physician attitude and management of financial toxicity. (2019) (2)
Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed? (2022) (2)
Impact of the Covid-19 pandemic on medical oncology utilization at a busy urban academic medical center (2020) (2)
Early and Standard Intervention with Epoetin Alfa (PROCRIT®) 120,000 Units (U) Every Three Weeks (Q3W) in Patients with Cancer Receiving Chemotherapy - Results of a Planned Interim Analysis. (2006) (1)
Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemia. (2006) (1)
Engaging Oncologists Toward Integrating a Shared Mental Model (SMM) for Palliative Oncology within a Large Academic Oncology Practice (TH341B) (2018) (1)
Advances in the Management of Chemotherapy-Induced Anemia and Its Treatment (2006) (1)
Abstract 342: Development and characterization of a novel anti-CLDN6 antibody drug conjugate for the treatment of CLDN6 positive cancers (2022) (1)
Erythropoietic therapy in the practice of oncology (2003) (1)
Darbepoetin alfa controversies, from dosage issues to safety concerns: the larger lesson. (2011) (1)
Patterns of Care in Patients with Chemotherapy Receiving Erythropoiesis Stimulating Agents (ESAs). (2007) (1)
Phase IV evaluation of clinical outcomes of PROCRIT in anemic cancer patients receiving chemotherapy (1994) (1)
Positive Early Breast Cancer : Results from the BCIRG Trastuzumab-Based Regimens in Patients with Node-Positive and High-Risk Health-Related Quality of Life With Adjuvant Docetaxel (2013) (1)
Survival in patients with locally advanced breast cancer after neoadjuvant docetaxel (T), carboplatin (C), and trastuzumab (H). (2009) (1)
Are there clinical benefits associated with treatment of mild chemotherapy-induced anemia (CIA)? A systematic review (2005) (1)
A randomized, double-blind, multicenter phase 2 trial of denosumab in combination with chemotherapy as first-line treatment of metastatic non-small cell lung cancer. (2014) (1)
476 PFS by patient subgroup for standard chemotherapies in combination with bevacizumab (BV) in the first-line treatment of HER2-negative locally recurrent (LR) or metastatic breast cancer (mBC): results from RIBBON-1 (2010) (1)
Use of Erythropoiesis-stimulating Agents (ESAs) in Lung Cancer Patients: Study-level and Patient-level Meta-analyses of Safety Outcomes (2010) (1)
Meta-analysis of the effects on safety of front-loading (FL), every-2-week (Q2W), and Q3W dosing of darbepoetin alfa (DA) in patients (pts) with chemotherapy-induced anemia (CIA). (2012) (1)
Open‐label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non‐myeloid malignancies (2022) (1)
Abstract PO-023: Impact of the Covid-19 pandemic on medical oncology utilization at a busy urban academic medical center (2020) (1)
Abstract CT103: Phase I study of LHC165 ± spartalizumab (PDR001) in patients (pts) with advanced solid tumors (2021) (1)
249: Inhibitory Effect of Dietary Fish Oil (Omega-3 Fatty Acids) on Human Prostate Cancer Progression in Severe-Combined Immunodeficient Mice (2005) (1)
1330TiPA PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER TRIAL OF DENOSUMAB IN COMBINATION WITH CHEMOTHERAPY AS FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER. (2014) (1)
Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma. (2022) (1)
Randomized controlled trials of the erythroid-stimulating agents in cancer patients. (2011) (1)
Initiating epoetin alfa (EPO) 120,000 U every three weeks (Q3W) in pts with chemotherapy (CT)-induced anemia (CIA) (2007) (1)
A digital oncology patient-reported outcomes platform: Building innovative electronic patient symptom assessments in epic mychart to improve the quality of life and survival of patients with advanced cancer. (2019) (1)
A methods study to define the performance specifications of MHC tetramer assays for immune monitoring of tumor immunotherapy. (2004) (1)
Early intervention with recombinant human erythropoietin for chemotherapy-induced anemia (2008) (1)
Every-three-week erythropoietic support during chemotherapy for cancer: current status and future issues. (2005) (1)
lymphoproliferative disorders cell patient with "atypical" hairy cell leukemia: evidence for distinct T and B Integrated human T-cell leukemia virus II genome in CD8 + T cells from a (2011) (1)
Cost-health literacy training in fellowship: A QI initiative. (2020) (1)
Darbepoetin alfa given once every 3 weeks (Q3W) either synchronously or asynchronously with Q3W chemotherapy (ctx) improves anaemia in patients with breast cancer: results of a randomised, open-label study (2004) (1)
469 Incidence of selected adverse events (AEs) in phase III studies of bevacizumab (BV) in combination with chemotherapy for the treatment of HER2-negative metastatic breast cancer (mBC) (2010) (1)
Analysis of Bevacizumab (Bev) Therapy, Bisphosphonate Use and Osteonecrosis of the Jaw (ONJ) in >1900 Patients Treated in Two Randomized, Controlled Trials. (2009) (1)
Clinical Advantages of Neoadjuvant Docetaxel (T) and Carboplatin (C) ± Trastuzumab (H) in Locally Advanced Breast Cancer (LABC). (2009) (1)
1139 POSTER Treatment patterns and patient characteristics associated with treatment for chemotherapy-induced anaemia in community-based oncology practices in the U.S. (2007) (1)
Cost-Health Literacy as an Educational Objective in Fellowship Training (2021) (0)
Erythropoiesis-Stimulating Agents and the Practice of Gynecologic Oncology (2008) (0)
Abstract OT2-02-05: A randomized trial of abemaciclib in combination with fulvestrant compared to chemotherapy in women with HR+, HER2- advanced breast cancer with visceral metastases (2020) (0)
A Phase III, Randomized, Multi-Center, Open-Label, Fixed Dose, Neulasta Active-Controlled Clinical Trial of F-627, a Novel G-CSF, in Women with Breast Cancer Receiving Myelotoxic Chemotherapy (2021) (0)
Abstract PO-089: The impact of Covid-19 on public generosity toward cancer-related crowdfunding efforts (2020) (0)
Abstract B86: Radiation and TGFβ blockade bring back memories in metastatic breast cancer patients (2017) (0)
Safety and Efficacy Results from iSABR, a Phase I Study of Stereotactic Ablative Radiotherapy (SABR) in Combination with Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer (NSCLC). (2023) (0)
Abstract PO-011: CiRCL: A psychosocial program facilitating communication and care to patients, families, and frontline health care teams during COVID-19 (2020) (0)
Current D evelopments i n C ancer V accines a nd Cellular I mmunotherapy (2003) (0)
Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer. (2023) (0)
Introduction (2001) (0)
zidovudine factor and erythropoietin decreases hematologic toxicity from Combined therapy with recombinant granulocyte colony-stimulating (2011) (0)
Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion (2012) (0)
Impact of a Palliative Care Nurse Practitioner in an Oncology Clinic: A Quality Improvement Effort (2021) (0)
Patients (pts) with solid tumors or lymphoproliferative malignancies (lympho) have similar dose response to darbepoetin alfa (2002) (0)
Reviews and Notes: Oncology: Clinical Oncology (1996) (0)
Shaping the Immune Landscape in Irradiated Breast Cancer Patients with Systemic TGF-β Blockade (2016) (0)
Preclinical and clinical trial results using Talazoparib and Low-Dose Chemotherapy. (2022) (0)
FRONT-LOADING WITH DARBEPOETIN ALFA PRODUCES OBSERVED IMPROVEMENTS IN HEMOGLOBIN RESPONSE AND HEALTH-RELATED QUALITY OF LIFE COMPARED WITH RECOMBINANT HUMAN ERYTHROPOIETIN (2003) (0)
Gemcitabine/Nab-Paclitaxel and Pamrevlumab in Locally Advanced Pancreatic Cancer (LAPC): A Phase 1/2 Trial (2019) (0)
Abstract 332: Development of a novel therapeutic CLDN18.2 monoclonal antibody and antibody drug conjugate for the treatment of CLDN18.2 positive cancers (2022) (0)
A provider-focused, point-of-care technology to improve clinical trial accrual. (2020) (0)
Stem Cell Factor (2000) (0)
Precision Oncology and Nutrition (2021) (0)
REDUCING ANEMIA AND FATIGUE IMPROVES PRODUCTIVITY IN PATIENTS WITH SOLID TUMORS (2003) (0)
Abstract 4044: Development of UCT-01-097, a novel orally available ERK1/2 inhibitor for the treatment of ERK1/2 dependent cancers (2023) (0)
T Cell Responses to Alpha Fetoprotein-Derived Immunodominant Peptide-Pulsed Dendritic Cells in Patients with Hepatocellular Cancer (2004) (0)
Holter monitor cardiac safety evaluation of vincristine sulfate liposomes injection (VSLI) administered to humans with active cancer. (2011) (0)
Assessment of Clinical Outcomes Following Erythropoietic Intervention at a Hemoglobin Concentration above 10 g/dL: A Comprehensive Review of Recent Literature. (2004) (0)
DENDRITIC CELLS AND VACCINES Treatment ofMetastatic Colorectal Cancer Patients with a Tumor Lysate Pulsed Dendritic Cell Vaccine: A Randomized Evaluation of Ex Vivo CD40L Activation (2004) (0)
Interaction of expectation on acupuncture as an antiemetic treatment (2010) (0)
Long-term risks of increased use of intravenous iron – Authors' reply (2007) (0)
MONITORING CHANGES IN GLUCOSE METABOLISM IN LIVER MELANOMA METASTASES SEQUENTIALLY TREATED WITH GM-CSF AND CYCLOPHOSPHAMIDE WITH FDG PARAMETRIC IMAGING AND PET (1992) (0)
Updates on SABCS 2003 Abstracts (2004) (0)
Adenovirus Lymphocytes by Dendritic Cells Transduced Generation of Melanoma-Specific Cytotoxic T (1998) (0)
Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors. (2023) (0)
Nivolumab Treatment of Burkitt Lymphoma: A Case Report (2020) (0)
Abstract P6-13-03: Not presented (2019) (0)
Can We Define the Mechanism of Antitumor Response Observed During Clinical Adoptive Immunotherapy (1997) (0)
Risks for Anaphylaxis With Intravenous Iron Formulations (2022) (0)
Cells in the Absence of CD8-Positive Cells Enhanced Tumor Responses to Dendritic (2013) (0)
How Might ESAs Alter Cancer Biology , Response to Treatment , or Survival ? (2009) (0)
Epoetin alfa improves hemoglobin levels and quality of life for lung cancer patients receiving chemotherapy (2000) (0)
Exceptional Response to Erda ﬁ tinib in FGFR2 -Mutated Metastatic Pancreatic Ductal Adenocarcinoma (2022) (0)
Objective Radiographic Response to MEK Inhibitor Therapy in a Patient with a Metastatic Melanoma with a BRAF (2012) (0)
Cancer Therapy: Clinical Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma (2009) (0)
Melanoma and sarcoma (2005) (0)
A careful reassessment of anthracycline use in curable breast cancer (2021) (0)
TCRM_A_243462 245..259 (2020) (0)
Author reply (0)
Cytokines in the Supportive Care of Cancer (2007) (0)
Encore Abstracts (2007) (0)
Society News June 2005 (2005) (0)
The UCLA-Community Breast Cancer Collaborative Clinical Translational Research Program (2002) (0)
Evaluating if darbepoetin alfa efficacy and safety in patients with chemotherapy-induced anemia is affected by the disease stage of the patient. (2016) (0)
Safety profile of histamine dihydrochloride administered with interleukin-2 in patients with advanced metastatic malignant melanoma (2001) (0)
1417: Growth Inhiditory Effects of a Low-Fat Diet on Prostate Cancer Cells in Vitro: Results of a Prospective Randomized Dietary Intervention Trial in Men with Prostate Cancer (2005) (0)
Standardization of MHC Tetramer and ELISPOT Assays To Quantitate Antigen-Specific T Cell Expansion after CTLA4 Blockade (2004) (0)
Initiating epoetin-alpha (EPO) 120,000 units (U) every three weeks (Q3W) in patients with chemotherapy (CT)-induced anemia (CIA) and a hemoglobin (Hb) of <11 g/dL (2007) (0)
Implementation and dissemination of a shared mental model of palliative oncology. (2019) (0)
Evaluating the Safety of Erythropoiesis-Stimulating Agents (ESAs) in Patients with Breast Cancer, Lung Cancer, and Hematologic Malignancies: A Meta-Analysis of Randomized, Controlled Trials. (2007) (0)
233 A phase IV study of epoetin alfa examining clinical outcomes in anaemic cancer patients receiving chemotherapy (1995) (0)
Commentary (Glaspy)—Thrombopoietin: Biology and Potential Clinical Applications (1998) (0)
cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. (2011) (0)
Management of Anemia in Patients With Cancer (2002) (0)
Neoadjuvant docetaxel (T), carboplatin (C), with or without trastuzumab (H) for T3 and T4 breast cancer (2005) (0)
Multicenter P hase I I S tudy o f O ral B exarotene f or P atients With M etastatic B reast C ancer (2003) (0)
PCN5 COMPARING THE COST-EFFECTIVENESS OF FRONT-LOADED DARBEPOETIN ALFA WITH EPOETIN ALFA FOR ANEMIA MANAGEMENT IN CHEMOTHERAPY-TREATED CANCER PATIENTS IN UNITED STATES (2002) (0)
Retroviral diseases in hematology. (1994) (0)
WEEKLY DARBEPOETIN ALFA DOSES OF 2.25 AND 4.5 MCG/KG PRODUCE HIGHER OBSERVED MEAN HEMOGLOBIN CHANGES THAN THREE TIMES WEEKLY RECOMBINANT HUMAN ERYTHROPOIETIN AT 150 OR 300 U/KG (2003) (0)
Anemia and Red Cell Factors (2008) (0)
WHOLE-BODY PET WITH FDG FOR DETECTION OF BOTH PRIMARY AND METASTATIC MALIGNANCIES: AN UPDATE OF THE CLINICAL EXPERIENCE (1992) (0)
Entering a new era in the management of tumor-associated involution. (2005) (0)
Evaluation of Hematologic Endpoints Used To Assess Erythropoiesis-Stimulating Agents (ESAs): A Pooled Analysis of Data from over 10,000 Patients (pts) with Chemotherapy-Induced Anemia (CIA). (2006) (0)
Author reply (0)
Abstract OT-13-01: A phase I study of preoperative ipilimumab, nivolumab, and talimogene laherparepvec for localized breast cancer (2021) (0)
Engaging oncologists toward integrating a shared mental model for palliative oncology within a large academic oncology practice. (2017) (0)
Economic Outcomes Associated With Hematopoietic Growth Factors (1995) (0)
CiRCL: A psychosocial program facilitating communication and care to patients, families, and frontline health care teams during COVID-19 (2020) (0)
Identifying resources available to physicians for management of financial toxicity: A Fellow-driven QI initiative. (2020) (0)
Evaluation of cancer detection with whole-body positron emission tomography (PET) and 2-[F-18]fluoro-2-deoxy-D-glucose (1993) (0)
iSABR: Safety and Efficacy Results from a Phase II Study of SABR in Combination with Durvalumab for Early-Stage Medically Inoperable NSCLC (2022) (0)
Characterization of Melanoma Antigen-Specific T Cells in a Long Term Survivor with Metastatic Melanoma with a Stable Peripheral Blood Population of Greater Than 5% of MART-1-Specific CD8+ T Cells (2004) (0)
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial (2023) (0)
Abstract 5991: Development and characterization of a novel CDK4/6 inhibitor for the treatment of CDK4/6 dependent cancers (2023) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With John A. Glaspy?

John A. Glaspy is affiliated with the following schools: